Drug Design Models for Human Diseases by Transgenic Animals

The procedures of drug research and preclinical trials are difficult, and a significant majority of medication candidates are unable to receive authorization from the United States Food and Drug Administration. To enhance the likelihood of success in the new drug development process, it is necessary to use efficient and predictive techniques that can identify high-quality targets. An effective approach to address the difficulties encountered in the advancement of novel medications and combination treatments is using cost-effective and easily controllable animal models for in vivo experimentation. The use of transgenic animals in the drug discovery laboratory as a model is considered an important tool for researching human diseases and determining responses to therapeutic intervention. These animals are genetically modified organisms that exhibit characteristics resembling symptoms of certain human illnesses. It offers genetic models of many human illnesses that are crucial for comprehending diseases and establishing novel targets. Since the 1980s, scientists have achieved the ability to manipulate the mouse genome via genetic modification, namely by eliminating or replacing a particular gene. ATryn, the first medication derived from transgenic animals, was produced and authorized by the United States Food and Drug Administration within 20 years of its creation. This breakthrough has paved the way for the development of pharmaceuticals derived from transgenic animals. One such application is the creation of biologically safe medications that are based on human regulatory proteins. Many issues, such as ethical concerns, regulatory requirements, and patents pertaining to the usage of transgenic animals, will get additional attention in the coming years. Transgenic animals play a critical role in drug discovery and development with potential applications in xenotransplantation, clinical trials, and other areas.